SomnoMedASX:SOM +0.94%50 Median PS Value is A$1.09 as of Jun. 27, 2026, which is 100% below its 10-year median of 0.50. GuruFocus rates ASX:SOM with a GF Score™ of 50/100 and a GF Value™ of A$0.45 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 338 Medical Devices & Instruments companies, SomnoMed ranks better than 70.71% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. SomnoMed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.55. SomnoMed's 10-Year median PS Ratio is 1.9818. Therefore, the Median PS Value for today is A$1.09.
As of today (2026-06-27), SomnoMed's share price is A$0.535. SomnoMed's Median PS Value is A$1.09. Therefore, SomnoMed's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for SomnoMed's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of SomnoMed was 1.21. The lowest was 0.13. And the median was 0.50.
ASX:SOM's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
SomnoMed (ASX:SOM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
SomnoMed's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.535
/
1.09
=
0.49
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed Median PS Value Related Terms
SomnoMed Median PS Value Historical Data
* Premium members only.
The historical data trend for SomnoMed's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SOM vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, SomnoMed's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SomnoMed Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where SomnoMed's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.9818.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SomnoMed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SomnoMed (ASX:SOM) has a Median PS Value of A$1.09 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on SomnoMed and its competitors. This is 118% above median its historical median of 0.50. Over the past decade, SomnoMed's Median PS Value has ranged from 0.13 to 1.21. According to the industry distribution chart, SomnoMed ranks #99 out of 338 companies in the Medical Devices & Instruments industry, placing it in the top 29.3%.
Is SomnoMed's Median PS Value too high?
SomnoMed's current Median PS Value of A$1.09 is 118% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 1.21. Based on the distribution chart, SomnoMed ranks #99 out of 338 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SomnoMed has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #99 out of 338 companies for Median PS Value. This puts SomnoMed in the upper half of its industry. The industry median Median PS Value is 0.71. Historically, SomnoMed's own Median PS Value has ranged from 0.13 to 1.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on SomnoMed and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SomnoMed's current Median PS Value is A$1.09, which is 118% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.54 — trading 18.9% above its estimated fair value. The current Median PS Value is A$1.09, which is 118% above median its 10-year median of 0.50. SomnoMed's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current Median PS Value is A$1.09 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SomnoMed (ASX:SOM) Overvalued in 2026?
Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued.
The current stock price of A$0.54 is trading 18.9% above its estimated GF Value™ of A$0.45.
GuruFocus considers SomnoMed to be Modestly Overvalued.
Key valuation signals for ASX:SOM:
Median PS Value: A$1.09 (118% above median its 10-year median of 0.50)
GF Value™: A$0.45 vs. price of A$0.54 (18.9% above fair value)
No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
50GF Score
Get the complete analysis for ASX:SOM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SOM has been successfully added to your 
